Related Experiment Video
Updated: Dec 20, 2025
09:28
Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
10.6K
[Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas]
1Department of Urology, First People's Hospital of Shanghai, Shanghai 200080, P. R. China.
AI Zheng = Aizheng = Chinese Journal of Cancer
|January 16, 2003
Summary
Cyclooxygenase-2 (COX-2) is upregulated in bladder transitional cell carcinoma (BTCC) and linked to tumor progression. This suggests COX-2 plays a key role in bladder cancer development.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Context:
- Cyclooxygenase (COX) enzymes are crucial for prostaglandin synthesis.
- COX-2 has been implicated in various carcinogenesis processes.
- Understanding COX expression in bladder cancer is vital for therapeutic strategies.
Purpose:
- To investigate the expression patterns of COX-1 and COX-2 in human bladder cancer tissues.
- To analyze the correlation between COX expression and clinicopathological parameters of bladder cancer.
- To elucidate the role of COX enzymes in the development and progression of bladder transitional cell carcinoma (BTCC).
Summary:
- Reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry were used to detect COX-1 and COX-2 mRNA and protein levels in BTCC, adjacent normal mucosa, and cystitis tissues.
- COX-2 mRNA and protein expression were significantly elevated in BTCC compared to normal and cystitis tissues.
- COX-2 expression intensity correlated positively with tumor grade and stage in BTCC, while COX-1 was constitutively expressed in normal tissues but downregulated in cancer.
Impact:
- The findings indicate that enhanced COX-2 expression is a hallmark of human BTCC.
- COX-2 may serve as a potential biomarker for bladder cancer progression and malignancy.
- Targeting COX-2 could represent a therapeutic avenue for bladder cancer treatment.
